Dermata TherapeuticsDRMA
13F holders, Q4 2024 (December 31)6holders +2
1new positions
0sold out
$1.35avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings, up 2 from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were Armistice Capital, LLC ($37K), UBS Group AG ($19K) and Wells Fargo & Company ($3K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $37K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 39,583 shares bought and 1,498 shares sold, net +38,085 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Armistice Capital, LLC | 0.00% | New | 27,200 | $37K |
| UBS Group AG | 0.00% | Add +826.8% | 13,874 | $19K |
| Wells Fargo & Company | 0.00% | No change | 2,045 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -51.8% | 1,394 | $2K |
| SBI Securities Co., Ltd. | 0.00% | — | 1,000 | $1K |
| Bank of America Corp. | 0.00% | Add +60.0% | 16 | $22 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.